First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021013563
Abstract: Severe hemophilia A is routinely managed with prophylactic replacement of factor VIII (F8), but a significant minority of patients develop anti-F8 antibodies. Extended half-life (EHL) products were developed to reduce the frequency of infusions required.… read more here.
Keywords: first study; life rfviiifc; half life; study extended ... See more keywords